权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

DNA-gated cytometry for multiplexed sorting of antigen-specific CD8 T cells

用于抗原特异性 CD8 T 细胞多重分选的 DNA 门控细胞术

基本信息

批准号：
10650429
负责人：
Gabriel A Kwong
金额：
$ 39.55万
依托单位：
GEORGIA INSTITUTE OF TECHNOLOGY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-06-20 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10650429
关键词：
Affinity Antibodies Antigens Avidity Benchmarking Binding Biological Assay CAR T cell therapy CD19 gene CD8-Positive T-Lymphocytes Cell Death Cell Fraction Cell Separation Cell Therapy Cell physiology Cells Couples Cytomegalovirus Cytometry DNA DNA Integration DNA Sequence Dissociation Engineering Fluorescence Fluorescence-Activated Cell Sorting Generations HLA-A2.1 Human Human Herpesvirus 4 Individual Infection Influenza K562 Cells Label Length Libraries Light Lymphocytic choriomeningitis virus Magnetism Major Histocompatibility Complex Mediating Modeling Molecular Mus Oligonucleotides Peptide/MHC Complex Peptides Phenotype Population Process Production Raji Cell Reaction Receptor Activation Receptor Cell Sampling Sorting Splenocyte T cell therapy T-Cell Receptor T-Lymphocyte T-Lymphocyte Epitopes T-cell receptor repertoire Technology Testing Transgenic Mice Ultraviolet Rays Viral Virus Virus Diseases Work adaptive immunity cancer cell chimeric antigen receptor T cells cytotoxicity design fluorophore in vivo magnetic beads manufacture mitochondrial dysfunction monomer mouse model neoplastic cell novel strategies prevent receptor shear stress success transduction efficiency translational potential

项目摘要

PROJECT SUMMARY Ag-specific CD8 T cells express T cell receptors (TCRs) that recognize antigens in the form of processed peptides bound to major histocompatibility complex class I (MHCI) molecules. In healthy individuals, the CD8 TCR repertoire comprises approximately 106–108 different cell populations. Soluble pMHCI multimers are widely used to enumerate and isolate Ag-specific T cells by fluorescence activated cell sorting (FACS); however, FACS has limitations including low-throughput, high shear-stress damage (especially to rare cells), and low multiplexing depth due to limited number of fluorophores. For high-throughput cell sorting (>106 cells) such as for manufacturing T cell therapies, magnetic activated cell sorting (MACS) is commonly used but can only produce antibody-enriched or depleted cell fractions, and cells sorted by positive selection remain labeled with beads, preventing immediate downstream assays such as phenotyping by flow analysis. New approaches are needed for multiplexed, high-throughput and label-free isolation of Ag-specific T cells. This proposal will develop DNA- gated sorting (DGS) cytometry for multiplexed isolation of Ag-specific CD8 T cells. DGS comprise a molecular DNA circuit that couples a magnetic bead to pMHCI molecules through DNA hybridization, and that functions as a sorting ‘gate’ to capture, release, and recover Ag-specific T cells by toehold-mediated strand displacement. By using orthogonal DNA strand displacement reactions, a library of beads coated with different pMHCI antigens can simultaneously capture target cell populations en masse and each subpopulation can then be eluted by sequential strand displacement. In contrast to fluorophores, the number of possible DNA sequences to design strand displacement reactions scales exponentially by the length n of the DNA oligo (i.e., 4n), providing the possibility to extend this technology to isolate Ag-specific T cells at depths that is currently not possible. This proposal will also implement DGS with pMHCI monomers that multimerize when hybridized onto the bead to produce the required binding avidity for T cell capture, but after cell release, revert into monomers to dissociate from T cells resulting in label-free isolates. It will also implement light-induced peptide exchange to produce large pMHCI libraries to integrate with multiplexed DGS. Finally, this proposal will demonstrate an important application for the manufacturing of chimeric antigen receptor (CAR) T cells using virus-specific T cells to redirect them to tumor cells, using key benchmarks such as ex vivo functional assays (expansion, transduction efficiency, cytotoxicity) and in vivo therapy in mice bearing CD19+ cancer cells.

项目总结